Adjuvant rituximab to prevent TTP relapse
摘要
In this issue of Blood, Page et al show that treatment with rituximab at the time of an initial episode of thrombotic thrombocytopenic purpura (TTP) is associated with a dramatic reduction in the risk of subsequent relapse. Their data raise the question of whether all or selected patients with a first episode of acquired TTP should be treated with adjuvant rituximab to prevent recurrence.1
引用本文（GB/T 7714）
Adam Cuker. Adjuvant rituximab to prevent TTP relapse[J]. Blood, 2016.
引文网络
本站仅收录题录与摘要供学习参考，全文版权归属出版方；如有侵权请联系我们删除。